pre-IPO PHARMA

COMPANY OVERVIEW

KSQ Therapeutics is pioneering High-Confidence Drug Development: a fundamentally new approach to R&D where the majority of the de-risking work is done prior to the generation of therapeutic drug candidates. Powered by our proprietary CRISPRomics™ drug discovery engine, our team has elucidated the function that each human gene plays in multiple diseases, providing a unique and more comprehensive understanding of disease biology. The quality of these insights enables our scientists to rapidly identify and validate high-confidence, patient-tailored, novel drug targets and then focus our collective efforts on the development of medicines with the greatest potential to impact the lives of patients. KSQ has initiated a pipeline of preclinical discovery programs and was founded in 2015.


LOCATION

  • Cambridge, MA, USA

  • THERAPEUTIC AREAS

  • Oncology

  • WEBSITE

    https://ksqtx.com/#home


    CAREER WEBSITE

    https://ksqtx.com/current-openings/


    SOCIAL MEDIA


    INVESTORS

    alexandria-venture-investments arch-venture-partners baillie-gifford cowen-healthcare-investments flagship-pioneering invus lilly-asia-ventures polaris-partners


    PRESS RELEASES


    Sep 6, 2023

    KSQ Therapeutics and CTMC Announce Strategic Collaboration to Accelerate the Development of Novel Engineered Tumor Infiltrating Lymphocyte (eTIL) Therapies for the Treatment of Solid Tumors


    Jul 13, 2023

    KSQ Therapeutics Enters Worldwide License Agreement with Roche for KSQ-4279, a Clinical-Stage USP1 Inhibitor for Cancer


    May 17, 2023

    KSQ Therapeutics and Takeda Expand Strategic Immuno-Oncology Collaboration to Identify and Validate Novel Tumor Targets


    Jan 25, 2023

    KSQ Therapeutics Announces Ono Pharmaceutical Co., Ltd. is Acquiring Multiple Research-Stage Oncology Programs Identified with KSQ’s CRISPRomics Platform Technology


    Dec 7, 2022

    KSQ Therapeutics Announces First Patient Dosed in Combination Portion of the Ongoing Phase 1 Study of KSQ-4279, a First-In-Class USP1 Inhibitor, in Patients with Advanced Solid Tumors


    For More Press Releases


    Google Analytics Alternative